Radiation-induced breast angiosarcomas are rare but recognized complication of breast cancer radiotherapy and are of poor prognosis. Little is known about the genetic abnormalities present in these secondary tumors. Herein, we investigated the differences in the genome and in the transcriptome that discriminate these tumors as a function of their etiology. Seven primary breast angiosarcomas and 18 secondary breast angiosarcomas arising in the irradiation field of a radiotherapy were analyzed. Copy number alterations and gene expression were analyzed using Affymetrix SNP 6.0 Array and Affymetrix Exon Arrays, respectively. We showed that two transcriptome signatures of the radiation tumorigenesis coexisted in these tumors. One was histology specific and correctly discriminated 100% of the primary tumors from the radiation-induced tumors. The deregulation of marker genes, including podoplanin (PDPN), prospero homeobox 1 (PROX-1), vascular endothelial growth factor 3 (VEGFR3) and endothelin receptor A (EDNRA), suggests that the radiation-induced breast angiosarcomas developed from radiation-stimulated lymphatic endothelial cells. None of the genes of the histology-specific signature were present in our previously published signature of the radiation tumorigenesis which shows the presence of a chronic oxidative stress in radiation-induced sarcomas of various histologies. Nevertheless, this oxidative stress signature classified correctly 88% of the breast angiosarcomas as a function of the etiology. In contrast, MYC amplification, which is observed in all radiation-induced tumors but also at a low rate in primary tumors, was not a marker of the radiation tumorigenesis.
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Introduction
The association between cancer rate and exposure to ionizing radiation is well documented by epidemiological investigations. All types of solid tumors are observed, with a prevalence of sarcomas and thyroid tumors (1) . The lack of specific pathological features that differ between radiation-induced and sporadic tumors has prevented determination of tumor etiology using rigorously defined scientific criteria. However, it has recently been shown that robust, blindly validated transcriptome signatures discriminate, case-by-case, the radiation-induced and the sporadic forms of post-radiotherapy sarcomas (2) and thyroid carcinomas (3) . Specific signatures were also found in post-Chernobyl thyroid carcinomas and post-radiotherapy breast cancers (4) . These first series of results showed the strength of the global approaches in the search for tumors etiology. Nevertheless, it is now necessary to specify the radiation-induced signatures and to determine if they contain genes characteristic of the tissue of origin of the tumor along with a more general set of genes valid for various histologies. In order to address these points, we focused here on breast angiosarcomas.
Angiosarcomas are a relatively rare histological subtype of sarcomas and represent ,1% of all sarcomas (5). They display remarkable clinical heterogeneity and can occur anywhere in the body, although the breast is a frequent location. Secondary sarcomas are a recognized complication of radiation therapy for breast carcinoma and are associated with poor prognosis (6). The estimated incidence of treatment-associated breast angiosarcoma is 0.002-0.05% per year (6, 7) corresponding to �40% of all radiation-induced sarcomas that develop after radiotherapy (8) . The standardized incidence ratio for a secondary angiosarcoma in irradiated breast cancer patients is 26 compared with 3.8 for any other sarcoma over a latency period of 5-10 years (9). In addition, primary breast angiosarcomas are also observed and represent �10-25% of all breast sarcomas (5) .
Little is known about the genetic abnormalities in secondary breast angiosarcomas; however, recurrent amplification of the 8q24.2 region containing the MYC oncogene was recently found in secondary but not in primary breast angiosarcomas (10) (11) (12) . High expression of the Myc protein was found to be associated with amplification, suggesting that MYC amplification may be implicated in the pathology of secondary breast angiosarcomas (11) .
In this study, we have undertaken the analysis of a series of primary and radiation-induced breast angiosarcomas using several complementary molecular approaches. We show that transcriptome signatures discriminate the tumors as a function of the etiology and that the radiation-induced breast angiosarcomas may derive from radiation-stimulated lymphatic endothelial cells.
Materials and methods

Biological material
Seven primary angiosarcomas and 18 secondary angiosarcomas arising in the radiation field of breast cancer radiotherapy were collected at the Biological Resources Center of the Institut Curie. All tumors originated from breast parenchyma and tumors from the skin above the breast were not retained. The study was approved by the ethics committee of the Institut Curie and informed consent was obtained from all patients. All patients'records were reviewed and the clinical information about the primary and secondary sarcomas was recorded. The hematoxylin-and eosin-stained sections of each tumor were reviewed by a pathologist (M.L.) to confirm the diagnosis of angiosarcoma. For secondary sarcomas, the patients' radiotherapy plans were reviewed by a radiopathologist (Y.K.) and it was verified that the tumors met the classic criteria of Cahan et al. (13) . These authors defined the criteria for the diagnosis of radiation-induced sarcomas: history of radiotherapy, asymptomatic latent period of several years, the occurrence of a sarcoma within a previously irradiated field and histological confirmation of the sarcomatous nature of the postirradiation lesion. Clinical details of the affected patients are summarized in Supplementary Table 1 , available at Carcinogenesis Online.
Preparation of nucleic acids
All preparations were conducted at the Biological Resources Center of the Institut Curie. DNA was extracted by phenol-chloroform treatment. An RNA was prepared using RNeasy Kits (Qiagen). The quality of the total RNA was verified by an Agilent 2100 Bioanalyser profile.
Whole-genome DNA copy number determination The Affymetrix Genome-Wide Human SNP Array 6.0 was used to detect copy number alterations. Samples were processed at the Genomic Platform of the Institut Curie following the instructions provided by the manufacturer. Data were normalized, analyzed and visualized using Partek Genomic Suite version 6.5 (Partek, St Louis, MO). Single nucleotide polymorphisms with smoothing values lower and greater than 2 ± 0.28 were considered as gain and loss, respectively. Microarray data were recorded in the ArrayExpress database (accession number: E-MEXP-3252).
Abbreviations: GPR, G protein-coupled receptor; miRNAs, micro RNAs; VEGF, vascular endothelial growth factor.
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Microarray expression analysis
Affymetrix Human Exon 1.0 ST arrays were hybridized at the Genomic Platform of the Institut Curie according the Ambion WT protocol (Life Technologies, France) and Affymetrix (Santa Clara, CA) labeling and hybridization recommendations. Total RNA (100 ng) was processed with an external MAQC, an RNA to check the robustness of the data. The mean yield of labeled DNA was 9.3 lg. Microarrays were hybridized with 4.7 lg of labeled DNA. Data quality control was performed using Expression Console (Affymetrix). Microarray data were recorded in the ArrayExpress database (accession number: E-MEXP-3271). Dataset analysis and visualization were done using EASANAÒ (GenoSplice technology, www.genosplice.com), which is based on the GenoSplice FAST DBÒ annotations (14, 15) . Exon Array data were normalized using quantile normalization. Background correction was done by using the antigenomic probes and probe selection was performed as described previously (16). Only probes targeting exons annotated from FAST DBÒ transcripts were selected in order to focus on well-annotated genes, whose messenger RNA sequences are in public databases (14, 15) . Among these selected probes, poor quality probes (e.g. probes labeled by Affymetrix as 'cross-hybridizing) and probes with signals of too low intensity compared with antigenomic background probes with the same GC content were removed from the analysis. Only probes with a detection above background P-value 0.05 in at least half of the arrays were considered for statistical analysis (16). Only genes expressed in at least one compared condition were analyzed. To be considered as expressed, the detection above background Pvalue had to be 0.05 for at least half of the gene probes. We first performed Student's t-test to compare gene intensities in the different biological replicates. Genes were considered significantly regulated when the fold change was !1.5 and the P-value 0.05. A subsequent analysis to determine a more robust signature was performed using Bonferroni correction of the P-value.
Hierarchical clustering
The distance from the gene signal in a given sample to the corresponding average in all the samples was calculated for each regulated gene. Corresponding values were displayed and clustered with MeV4.6.2 from the Institute of Genome Research using the Pearson's correlation and average linkage clustering.
Quantitative PCR micro RNA expression analysis Expression of the micro RNAs (miRNAs) present in the PVT1 locus (miR-1205, miR-1206, miR-1207-3P, miR-1207-5P and miR-1208) was analyzed using the TaqMan Human miRNA assays (Applied Biosystems) after reverse transcription using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems).
Quantitative PCR MYC amplification and expression analysis Amplification and expression of MYC were measured by real-time quantitative PCR (Q-PCR) and reverse transcription PCR (RT-Q-PCR), respectively. Complementary DNAs were prepared using the SuperScript II system according to the manufacturer's protocol (Invitrogen). DNAs and complementary DNAs were amplified using the GeneAmp 7500 sequence detection system and SYBR Green PCR Kits (Applied Biosystems) as described previously (17) . Expression was normalized using the GAPDH gene. Expressions were then compared using the case with the lower expression (PR04) as reference. Primer sequences are presented in Supplementary Table 2, available at Carcinogenesis Online.
Fluorescence in situ hybridization of MYC Interphase fluorescence in situ hybridization with a MYC dual color probe (Vysis; Abbott Laboratories, IL) was performed on formalin-fixed paraffinembedded tumoral tissue sections using a protocol previously described (18) . Probes for both MYC-specific DNA sequences and the centromere of chromosome 8 were labeled in red and green, respectively. The number of green and red signals was counted in at least 100 nuclei of invasive tumor cells, in two distant areas of the section at high magnification.
Results and discussion
Genome abnormalities
Single nucleotide polymorphism analysis showed that numerous copy number variations were present at various rate in the genome of the breast angiosarcomas (data not shown). In order to focus on the most recurrent abnormalities discriminating tumors as a function of etiology, we used stringent criteria in the selection of the regions of interest. Differences in gain or loss of chromosome segments between primary and radiation-induced breast angiosarcomas were considered as significant if (i) regions were only gained or lost, (ii) .50% of the tumors of one of the etiologies were concerned and (iii) the P-value was ,0.01. A single locus matched these criteria. The 18 radiationinduced angiosarcomas and one of the 7 primary angiosarcomas (PR06) showed amplification in the 8q24 region ( Figure 1A ). The amplified regions ranged from 0.65 to 3 Mb in length, possibly in several discontinuous regions, and all amplified regions contained MYC (Supplementary Table 3 , available at Carcinogenesis Online).
The miRNAs, miR-1205, miR-1206, miR-1207 and miR-1208, present in the PVT1 locus, often found to be amplified with MYC in cancer (19, 20) , were amplified only in a fraction of the tumors (Supplementary  Table 4 , available at Carcinogenesis Online). None of these miRNAs, analyzed by RT-Q-PCR, were expressed at a significant level in the tumors (data not shown). The single nucleotide polymorphism variants rs6983267 and rs16901979 associated with increased risk of prostate and colorectal cancers (21, 22) were recurrently included in the amplicons (Supplementary Table 1 , available at Carcinogenesis Online). However, none of the analyzed cases, with or without amplification, harbored the cancer risk variants (data not shown). The amplification of MYC was also determined by Q-PCR (Figure 2A ). The copy number was 2 for the primary angiosarcomas except for PR06 (140 copies). For the radiation-induced tumors, the copy number ranged between 16 and 125. Finally, the number of copies of MYC was estimated by Fluorescence in situ hybridization ( Figure 1B ). All the radiation-induced angiosarcomas and the primary case PR06 showed MYC amplification. Comparisons between the three quantification methods are presented in Supplementary Figure 1 , available at Carcinogenesis Online.
In good agreement with us, Guo et al. (11) and Mentzel et al. (12) found 100% of MYC amplification in radiation-induced breast angiosarcomas, whereas it was found in ,50% by Manner et al. (10) . The lower rate of amplification found in the later study could be related to the low resolution of the comparative genomic hybridization-array approach used. In these studies, MYC amplification was not found in primary angiosarcomas. Its low occurrence in our series suggests that it was not found in the other studies because few cases were analyzed.
In cases with amplification, MYC was overexpressed as compared with the non-amplified cases ( Figure 2B ). The normalized expression values ranged from 1 to 3.4 without amplification and from 4.5 to 200 with amplification. The levels of expression and of amplification were loosely linked (Supplementary Figure 1 , available at Carcinogenesis Online). The recurrence of MYC amplification and overexpression in radiation-induced breast angiosarcomas suggests that it is a major event in the tumoral development, although its low frequency in primary tumors indicates that it is not a marker of the radiation tumorigenesis.
Comparison of angiosarcoma genomes as a function of their MYC status using the same stringent criteria than as used for etiology showed that two regions of chromosome 3 matched. In all cases with MYC amplification, hemizygous deletions were observed in the 60.1-60.8 Mb region of the fragile histidine triad gene (FHIT) (Supplementary Figure 2 , available at Carcinogenesis Online). Deletions of one copy of the N-acetylated alpha-linked acidic dipeptidase-like 2 (NAALADL2) gene, at position 174-175 Mb, were present in 63% (12/19, including the primary case PR06) of the tumors with MYC amplification (Supplementary Figure 3 , available at Carcinogenesis Online). In the absence of MYC amplification, neither gene was deleted. By comparison with angiosarcomas without MYC amplification, transcriptome analysis showed that tumors with amplification slightly underexpressed FHIT and NAALADL2, but these differences were not significant (fold change 5 À1.2, P 5 0.3 and fold change 5 À2, P 5 0.11, respectively).
The recurrent amplification of MYC and of the loss of one allele of FHIT and NAALADL2 in the same radiation-induced tumors indicated a major role for these genes. The involvement of MYC in cancer has been extensively studied (23) and the tumor suppressor properties of FHIT are related to its pro-apoptotic effects (24) . The function of NAALADL2 is largely unknown, but it is involved in Kawasaki disease, an inflammatory vasculitis characterized by a propensity for coronary artery damage (25) . It can be assumed that during tumor formation, there was a genome instability phase, allowing the selection of the pathway characterized by the MYC/FHIT/NAALADL2 gene rearrangements. Its frequent presence in the radiation-induced tumors could be explained by the etiology. It is now well established that genome instability induced by ionizing radiation through direct or bystander effects is clonally hereditable (26) . This instability is characterized by deletions, amplifications and chromosome rearrangements and the fragile sites are its preferential targets (27) . MYC, FHIT and NAALADL2 are located at fragile sites: FRA8C-8D, FRA3B and FRA3C, respectively. Thus, the radiation-induced breast angiosarcomas could have been initiated by the selection of genome rearrangements induced by the radiation-induced genome instability. The same rearrangements were found in one of the seven primary cases of the series, an indication that the pathway activated by genome instability could be involved in breast angiosarcomas independently of the irradiation context. This tumor presented no clinicopathological difference from other primary cases and the nature of the factors involved in the selection of this pathway in primary angiosarcoma is not known, but it cannot be associated with a specific tumor form linked to the youth of the patient at the diagnosis (19 years) since two other primary cases were also in patients 19-20 years old (Supplementary Table 1 , available at Carcinogenesis Online).
Identification of transcriptome signatures discriminating radiation-induced and primary breast angiosarcomas
Comparison of the global messenger RNA expression panels of radiation-induced and primary angiosarcomas allowed us to establish a list of 2831 differentially regulated genes (759 upregulated and 2072 downregulated in the radiation-induced tumors, fold change .1.5, P , 0.05) (Supplementary Table 5 , available at Carcinogenesis Online). However, these genes did not correctly classify all the tumors as a function of their etiology (data not shown). In order to select the most relevant genes, a Bonferroni correction (P , 0.05) was applied and a series of 53 genes corresponding to 42 well-annotated genes (9 upregulated and 33 downregulated, Table I ) were obtained which discriminate radiation-induced and primary breast angiosarcomas independently of their grade of differentiation (Figure 3) . MYC was absent from the list, a confirmation that its expression was not a marker of the radiation tumorigenesis.
Analysis of the deregulated genes suggests that marker genes of the lymphatic endothelial cells were deregulated in radiation-induced breast angiosarcomas (Table I) . PDPN which encodes podoplanin, a small transmembrane glycoprotein specifically expressed in lymphatic vascular endothelium (28) , was overexpressed, whereas the endothelin receptor A (EDNRA), expressed at low level in lymphatic as compared with vascular endothelial cells (29) , was downregulated (Table I ). In our series, upregulation of PDPN and downregulation of EDNRA were enough to discriminate the angiosarcomas as a function of their etiology. However, several other genes not included in the stringent signature but differentially expressed must be considered. The prospero homeobox 1 (PROX-1), which controls the expression of PDPN (30), was strongly upregulated in radiation-induced angiosarcomas (fold change 5 þ9.72, P 5 1.8 E �5 ) Table 5 , available at Carcinogenesis Online). A fourth known marker of lymphatic endothelial cells was deregulated in radiation-induced angiosarcomas, the fms-related tyrosine kinase 4 (FLT4) gene which encodes a receptor for vascular endothelial growth factors C and D (VEGFR3) involved in lymphangiogenesis (31) . VEGFR3 was amplified in three tumors (PR06, RI12 and RI27, Supplementary Table 6, available at Carcinogenesis Online). The amplification of this gene was previously proposed as a marker of the radiation tumorigenesis (11) . However, in our series, FLT4 amplification was not a characteristic of the radiation-induced breast angiosarcomas since it was present in the primary case PR06. All the tumors with FLT4 amplification overexpressed VEGFR3 (Supplementary Table 6 , available at Carcinogenesis Online). Nevertheless, if only tumors without amplification were considered, VEGFR3 was overexpressed in radiation-induced as compared with primary breast angiosarcomas (fold change 5 5.2, P 5 4.78 E À6 ). Thus, in the absence of gene amplification, VEGFR3 overexpression was a marker of the radiation tumorigenesis.
These genes are considered as robust markers of lymphatic endothelial cells (32) . However, comparative microarray analyses of primary lymphatic and blood vascular endothelial cell transcriptomes revealed that $2% of the transcribed genes were differentially expressed (33) (34) (35) . Unfortunately, the overlap between the published gene lists was poor. Three genes were found to be upregulated in lymphatic endothelial cells in these three studies and also significantly upregulated in our radiation-induced breast angiosarcomas (Supplementary Table 7 , available at Carcinogenesis Online). RELN which codes for Reelin, a protease of the extracellular matrix which degrades fibronectin and laminin (36) , was found to be specifically expressed in lymphatic endothelial cells by immunohistochemical staining (37) . The mannose receptor 1 (MRC1) is a lectin which binds high mannose structures. In addition to macrophages, it is abundantly present in lymphatic endothelial cells where it directs the binding of cancer cells (38, 39) . The function of the trefoil factor (TFF3) is presently not known and a role in endothelial cells is not documented, but TFF3 is overexpressed in a variety of cancers (40) and predicts metastatic breast cancers (41) . Among the 10 other genes differentially deregulated in only two of the three studies on primary lymphatic and blood vascular endothelial cells, 5 genes (CD44, CDH2, IL4A, VCAN and VEGFR1) were also significantly deregulated in our radiationinduced breast angiosarcomas (Supplementary Table 7 , available at Carcinogenesis Online).
Altogether, our data show that radiation-induced breast angiosarcoma cells harbored markers of lymphatic endothelial cells. In line with this conclusion, in their study of skin biopsies from patients previously treated by radiotherapy for a primary breast cancer, Jackowski et al. (42) found, 1 year after irradiation, an increase of the podoplanin-positive lymphatic microvessel density in the irradiated regions. In addition, it is noteworthy that the suggestion of a lymphatic endothelial cell origin for Kaposi's sarcoma tumors was based on the expression of the same lymphatic markers as those found here in breast radiation-induced angiosarcoma (43,44) .
The G protein-coupled receptor 1 (GPR1) gene was the most overexpressed in radiation-induced breast angiosarcomas (Supplementary Table 5 , available at Carcinogenesis Online). The function of GPR1 is presently not known. However, it has been shown that some GPRs are involved in lymphangiogenesis and lymphatic vascular diseases (45) and that the Kaposi's sarcoma-associated herpes virus GPR upregulates the expression of vascular endothelial growth factors (46) . Understanding radiation-induced angiosarcomagenesis will require the functional analysis of the GPR1's role in endothelial cells.
Remarkably, none of the genes of the 53 genes signature defined here was present in our previously established signature, which discriminated sporadic and radiation-induced sarcomas (2) . This 135 gene signature (124 genes with known annotation) was established using cases including osteosarcomas, leiomyosarcomas and angiosarcomas with an approach minimizing the influence of histology. This signature was robust and correctly blindly classified as a function of their etiology 83% of the sarcomas of various histologies of the validation set (2) . Using this signature, the breast angiosarcomas were correctly classified as a function of their etiology with three errors: RI01 and RI06 clustered with the primary cases and PR06 was classified as radiation-induced (Supplementary Figure 4 , available at Carcinogenesis Online). Thus, the robustness of this signature was confirmed since 88% (22/25) of the breast angiosarcomas were correctly classified. In contrast, the 53 genes of the radiation-induced breast angiosarcoma signature failed to correctly classify the previously studied sarcomas of various histologies (2) as a function of the etiology (data not shown).
The function of the genes present in the histology independent signature of the radiation tumorigenesis (2) shows that radiationinduced sarcomas are characterized by chronic endogenous oxidative stress generated by mitochondrial dysfunction. In the signature specific to radiation-induced breast angiosarcoma, several additional genes can be related to this process (Table I ). The protein kinase C, theta (PRKCQ) was upregulated in radiation-induced sarcomas, whereas the nuclear receptor coactivator 2 (NCOA2) and calpain 3 (CAPN3) were both downregulated. PRKCQ plays a crucial role in the signaling pathways necessary for mitochondrial reactive oxygen species production (47) . NCOA2 participates to the mitochondrial respiration regulation (48) and the mitochondrial abnormalities leading to oxidative stress in calpainopathy are associated with CAPN3 deficiency (49) . In addition, the downregulation of aminoadipate-semialdehyde synthase (AASS) and of aminoadipate aminotransferase (AADAT), both of which are involved in the mitochondrial lysine degradation, could induce accumulation of lysine generating oxidative stress (50) . Thus, our data suggest that the 135 gene signature of chronic oxidative stress constitutes the core of the deregulated genes associated with mitochondrial dysfunction which allows us to discriminate between radiation-induced and non-radiation-induced sarcomas independently of their histology. However, in addition, specific pathways may be involved depending on the histology. Altogether, these data point to the diversity of the pathways used in radiation-induced sarcomas subject to oxidative stress. In summary, we demonstrate here that two distinct transcriptome signatures coexist in radiation-induced breast angiosarcomas and that both discriminated the tumors as a function of their etiology. One found in all sarcomas independently of their histology was previously identified (2) . It indicates the presence of chronic oxidative stress generated by mitochondrial dysfunction. The second signature was specific to the breast angiosarcomas. The deregulation of marker genes suggests that radiation-induced breast angiosarcomas develop from radiation-stimulated lymphatic vessel endothelial cells. In addition, we show that the high rate of MYC amplification found in radiation-induced breast angiosarcomas, which is likely a consequence of genome instability initiated by ionizing radiation, is not a marker of the radiation tumorigenesis since it is also observed at a low rate in primary tumors. Fold change: positive when upregulated in the radiation-induced sarcoma and negative when downregulated. P-value: adjusted with Bonferroni correction.
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